General Prognostic Models May neglect Vulnerable Subgroups in ANCA-associated Vasculitis

Overview

Journal J Nephrol

Publisher Springer

Specialty Nephrology

Date 2023 Sep 28

PMID 37768548

Authors

Martin Russwurm

Birgit Kortus-Goetze

Tanja Maier-Giebing

Hermann-Josef Groene

Joachim Hoyer

Affiliations

Soon will be listed here.

Abstract

Background: ANCA-associated vasculitis is an organ and life-threatening disease with the highest incidence in elderly patients. However, few studies have focussed on characteristics and treatment outcomes in a direct comparison of elderly and younger patients.

Methods: In a retrospective, single-centre, renal biopsy-cohort, patients were dichotomized by age ≥ 65 years to analyse baseline clinical, histological, laboratory and immunological characteristics and outcome differences in elderly and younger patients as regard to mortality, renal recovery from dialysis and eGFR after two years.

Results: In the biopsy registry, n = 774 patients were identified, of whom 268 were ≥ 65 years old. Among them, ANCA-associated vasculitis was the most prevalent kidney disease (n = 54 ≈ 20%). After a follow-up of 2 years, overall mortality was 13.4%, with 19% and 4% in patients ≥ and < 65 years of age, respectively. While 41% of elderly and 25% of younger patients were dialysis-dependent at the time of biopsy, renal recovery was achieved in 41% and 57% of patients, respectively. The accuracy of prediction differed significantly between the whole cohort and elderly patients as regard to mortality (sensitivity 46% vs. 90%, respectively) and between younger and elderly patients as regard to eGFR (r = 0.7 vs. 0.46, respectively). Age-group-wise analysis revealed patients above 80 years of age to have particularly dismal renal outcome and survival.

Conclusion: In our cohort, ANCA-associated vasculitis is the single most frequent histopathological diagnosis among the elderly patients in our cohort. Elderly and younger patients have comparable chances of recovering from dialysis-dependent renal failure, with comparable residual independent kidney function after two years. This study suggests (1) relevant predictors differ between age groups and hence (2) models involving all patients with ANCA-associated vasculitis neglect important features of vulnerable subgroups, i.e., patients above 80 years old.

References

Harper L, Savage C . ANCA-associated renal vasculitis at the end of the twentieth century--a disease of older patients. Rheumatology (Oxford). 2004; 44(4):495-501. DOI: 10.1093/rheumatology/keh522. View

Watts R, Lane S, Bentham G, SCOTT D . Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000; 43(2):414-9. DOI: 10.1002/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0. View

Pagnoux C, Hogan S, Chin H, Jennette J, Falk R, Guillevin L . Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 2008; 58(9):2908-18. PMC: 2754705. DOI: 10.1002/art.23800. View

Haris A, Polner K, Aranyi J, Braunitzer H, Kaszas I, Mucsi I . Clinical outcomes of ANCA-associated vasculitis in elderly patients. Int Urol Nephrol. 2014; 46(8):1595-600. DOI: 10.1007/s11255-014-0717-y. View

Weiner M, Goh S, Mohammad A, Hruskova Z, Tanna A, Bruchfeld A . Outcome and treatment of elderly patients with ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2015; 10(7):1128-35. PMC: 4491279. DOI: 10.2215/CJN.00480115. View

Chen M, Yu F, Zhang Y, Zhao M . Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine (Baltimore). 2008; 87(4):203-209. DOI: 10.1097/MD.0b013e31817c744b. View

Bomback A, Appel G, Radhakrishnan J, Shirazian S, Herlitz L, Stokes B . ANCA-associated glomerulonephritis in the very elderly. Kidney Int. 2010; 79(7):757-64. DOI: 10.1038/ki.2010.489. View

Gavazzi G, Krause K . Ageing and infection. Lancet Infect Dis. 2002; 2(11):659-66. DOI: 10.1016/s1473-3099(02)00437-1. View

McGregor J, Negrete-Lopez R, Poulton C, Kidd J, Katsanos S, Goetz L . Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol Dial Transplant. 2015; 30 Suppl 1:i171-81. PMC: 4597373. DOI: 10.1093/ndt/gfv045. View

10.

Yang L, Xie H, Liu Z, Chen Y, Wang J, Zhang H . Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. BMC Nephrol. 2018; 19(1):138. PMC: 6002994. DOI: 10.1186/s12882-018-0933-2. View

11.

Chung S, Langford C, Maz M, Abril A, Gorelik M, Guyatt G . 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken). 2021; 73(8):1088-1105. DOI: 10.1002/acr.24634. View

13.

Groot K, Harper L, Jayne D, Flores Suarez L, Gregorini G, Gross W . Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009; 150(10):670-80. DOI: 10.7326/0003-4819-150-10-200905190-00004. View

14.

Stone J, Merkel P, Spiera R, Seo P, Langford C, Hoffman G . Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010; 363(3):221-32. PMC: 3137658. DOI: 10.1056/NEJMoa0909905. View

15.

Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P . Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014; 371(19):1771-80. DOI: 10.1056/NEJMoa1404231. View

16.

Brix S, Noriega M, Tennstedt P, Vettorazzi E, Busch M, Nitschke M . Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018; 94(6):1177-1188. DOI: 10.1016/j.kint.2018.07.020. View

17.

Moutzouris D, Herlitz L, Appel G, Markowitz G, Freudenthal B, Radhakrishnan J . Renal biopsy in the very elderly. Clin J Am Soc Nephrol. 2009; 4(6):1073-82. PMC: 2689880. DOI: 10.2215/CJN.00990209. View

18.

Jefferson J . Treating elderly patients with ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2015; 10(7):1110-3. PMC: 4491287. DOI: 10.2215/CJN.05350515. View

19.

Hamour S, Salama A . ANCA comes of age-but with caveats. Kidney Int. 2011; 79(7):699-701. DOI: 10.1038/ki.2010.558. View

20.

Jayne D, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L . Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007; 18(7):2180-8. DOI: 10.1681/ASN.2007010090. View

21.

Pagnoux C, Quemeneur T, Ninet J, Diot E, Kyndt X, de Wazieres B . Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015; 67(4):1117-27. DOI: 10.1002/art.39011. View